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Abstract
Background. The benefits of steroid therapy in im-
munoglobulin A nephropathy (IgAN) have not been es-
tablished.
Methods. The effect of steroids on kidney survival was
retrospectively investigated in 702 patients with IgAN by
multivariate analyses.
Results. There were 295 men and 407 women. The median
follow-up period was 62 months. One hundred and ninety-
four patients were treated with oral steroids (oral steroid
group). Thirty-four patients were treated with methylpred-
nisolone (mPSL) pulse therapy (pulse steroid group) fol-
lowed by oral prednisolone (PSL). In 474 patients, no
steroid was used (no steroid group). The urinary protein-
creatinine ratio and histological grade were significantly
different among treatment groups and were highest in the
pulse steroid group followed by the oral steroid group and
lowest in the no steroid patients. Serum creatinine was sig-
nificantly higher in the pulse steroid group than in other
two groups. Eighty-five patients developed end-stage re-
nal failure (ESRF) requiring haemodialysis. In multivariate
analysis, steroid pulse therapy significantly decreased the
risk of ESRF while oral steroid treatment did not improve
renal survival in this cohort.
Conclusion. We found that pulse steroid therapy improved
kidney survivals in IgAN. Since the clinical findings and
histological grade were the most severe in patients treated
with mPSL pulse therapy, such therapy may prevent pro-
gression of IgAN.
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Introduction
Since Kobayashi et al. first reported the efficacy of steroid
treatment in patients with immunoglobulin A nephropathy
(IgAN) in 1986 [1], there has been widespread interest
in corticosteroid therapy for IgAN [2–17]. However, the
efficacy of steroid treatment has not yet been clarified.
In 2003, we reported a randomized control trial (RCT) in
patients with IgAN with a glomerular score between 4 and
7, and showed that a low-dose prednisolone (PSL) protocol
(20mg/dayasinitialdose)hadananti-proteinuriceffectbut
no effect on kidney survival [17,18]. We speculated that an
insufficient dose of PSL caused a discrepant effect on pro-
teinuriaandonkidney survival.Furthermore,pulsetherapy
has shown promising results in previous trials [14,17].
The aim of this study was to evaluate the effect of steroid
treatment on kidney survival in patients with IgAN. We
retrospectively investigated the influence of pulse and oral
steroid treatment on kidney survival in 702 patients with
IgAN by multivariate analyses using the Cox proportional
hazards model.
Materials and methods
Study population
Seven hundred and ninety-four patients with primary
IgAN, who had been biopsied between October 1979 and
September 2002, were followed up at least 1 year later at
Fukuoka Red Cross Hospital. Ninety-two biopsies, which
contained <10 glomeruli, were excluded. The remaining
702 patients were included in the study. There were no
statistical significant differences in age, sex, urine protein-
creatinine ratio (UP-UCR), serum creatinine and incidence
of end-stage renal failure(ESRF) between the702 included
patients and 92 excluded patient.
Histological grade based on the glomerular score
As previously reported [18,19], the glomerular score was
calculated as the sum of indices of the following three
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glomerular lesions: (1) hypercellularity; (2) segmental le-
sions, including crescent, tuft necrosis, tuft adhesion and
segmental sclerosis, and (3) global sclerosis.
The glomerular hypercellularity was defined as three or
more nuclei in the mesangial area, or endocapillary hyper-
cellularity in any extent. Each glomerulus in a biopsy spec-
imenwasgiven apoint according tothesemi-quantitatively
evaluated extent of involved area by hypercellularity as fol-
lows: 1, no hypercellularity; 2, <25% of the glomerular
area; 3, 25–50% and 4, ≥50% of the glomerular area. An
averageofpointsineachbiopsywascalculatedandomitted
for the figures below the first decimal place. We termed it
as the glomerular hypercellularity index.
Crescents,tuftnecrosis,tuftadhesionstoBowman’scap-
sule and segmental sclerosis of glomeruli were evaluated
together and termed glomerular segmental lesions, because
theselesionswereobservedtobefrequentlyassociatedwith
each other.
The index of segmental lesions and the index of global
sclerosis were determined according to the percentage of
glomeruli showing each lesion out of the total number
of glomeruli in a biopsy sample as follows: 0, none; 1,
<10% of glomeruli; 2, 10–25%; 3, 25–50% and 4, ≥50%
of glomeruli.
The points of indices of three lesions, i.e. hypercellu-
larity, segmental lesions and global sclerosis, were added
together and termed as the glomerular score, ranging from
1t o1 2 .
Histological grade was determined on the basis of the
glomerular score as follows: grade I, glomerular score 1 or
2; grade II, glomerular score 3 or 4; grade III, glomerular
score 5 or 6; grade IV , glomerular score 7 or 8 and grade V ,
glomerular score ≥9.
Theglomerularscoreofallkidneybiopsiesinthepresent
study were evaluated by one investigator (R.K.). As the
glomerular score was determined in 1991, kidney biop-
sies performed before 1991 were re-evaluated by the same
person.
Study design and statistics
Theinfluenceofclinicalparameters,histologicalgradeand
treatment onkidney survival was retrospectively examined.
The end point of kidney survival was estimated by ESRF
requiring haemodialysis therapy. Clinical parameters used
for analyses included age, sex, UP-UCR, blood pressure,
serum albumin, serum creatinine, total serum cholesterol,
serum triglyceride and serum uric acid. As for the treat-
ment, the effect of the method of steroid therapy, the use of
theangiotensinconvertingenzymeinhibitor(ACE-I)oran-
giotensin II receptor blocker (ARB), or tonsillectomy was
examined. The use of ACE-I or ARB was defined as treat-
ment for at least 6 months. Any antihypertensive agent was
permitted to control blood pressure during the follow-up.
The SAS software package was used to perform all sta-
tistical analyses. Renal survival in all patients was assessed
by the life table method and the log rank statistic. Com-
parisons among the groups were assessed by the chi-square
method, analysis of variance or Kruskal–Wallis method.
The statistical significances of the differences in mean of
continuous variables, median values or frequencies of cate-
Table 1. Baseline characteristics of study population
Variables
Number 702
Duration of follow-up (months) 62 (6–281)
Age (years) 33 ± 14
Men/women 295/407
Systolic blood pressure (mmHg) 126 ± 19
Diastolic blood pressure (mmHg) 75 ± 14
Urinary protein-creatinine ratio 1.5 ± 1.9
Urinary haematuria 2.2 ± 0.9
Serum albumin (g/dl) 4.2 ± 0.5
Serum creatinine (mg/dl) 0.98 ± 0.58
Serum uric acid (mg/dl) 5.6 ± 1.6
Serum total cholesterol (mg/dl) 198 ± 45
Serum triglycerides (mg/dl) 123 ± 95
Serum IgA (mg/dl) 366 ± 126
Histological grade, n (%)
Grade I (glomerular score 1 or 2) 114 (16.2)
Grade II (glomerular score 3 or 4) 208 (29.6)
Grade III (glomerular score 5 or 6) 203 (28.9)
Grade IV (glomerular score 7 or 8) 145 (20.7)
Grade V (glomerular score >9) 32 (4.6)
Steroid therapy, n (%) 228 (32.3)
Use of ACE-I or ARB, n (%) 241/659 (36.6)
Tonsillectomy, n (%) 28/623 (4.5)
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin-II re-
ceptor blocker.
Duration of follow-up is median (range).
Values are means ± standard deviation or frequencies.
Note:Toconvertserumcreatinineinmg/dltoµmol/l,multiplyby88.4.To
convert serum uric acid in mg/dl to µmol/l, multiply by 59.5. To convert
triglycerideinmg/dltommol/l,multiplyby0.0113.Toconvertcholesterol
in mg/dl to mmol/l, multiply by 0.026. To convert serum IgA in mg/dl to
g/l, multiply by 0.01.
gorical variables between the two groups were determined
by the multiple t-test, Mann–Whitney U-test or chi-square
test with Bonferroni correction.
The crude or multivariate-adjusted hazard ratios (HRs)
and95%confidenceintervals(CIs)wereestimatedwiththe
useoftheCoxproportionalhazardsmodel.Inthemultivari-
ate model, we selected clinically or biologically plausible
risk factors for the determination of kidney survivals as
baseline potential confounding factors [19,20], and used
the backward procedure with P<0.05 required to retain
each variable in the model including age and sex. Because
21 patients changed treatment groups during the follow-up
(12 patients, no steroid to oral steroid; 5 patients, no steroid
to pulse therapy; 4 patients, oral steroid to steroid pulse
therapy), we also estimated the effect of steroid therapy us-
ing the time-dependent Cox proportional hazard regression
modelincludingthetime-dependentstatusoftreatmentand
covariates.
P<0.05 was considered statistically significant.
Results
The baseline characteristics of the study population
The baseline characteristics of the patients are shown in
Table1.Themedianfollow-upperiodwas62months,rang-
ing from 6 to 281 months. Eight patients developed ESRFThe improvement of renal survival with steroid pulse therapy 3917
Table 2. Baseline characteristics of treatment groups
Variables No steroid Oral steroid Pulse steroid P
Number 474 194 34
Number of ESRF 57 21 7
Median duration of follow-up, months (range) 62 (6–281) 69 (7–240) 44 (11–147)b 0.031
Age (years) 33 ± 14 33 ± 13 33 ± 18 n.s.
Men/women 192/282 84/110 19/15 n.s.
Systolic blood pressure (mmHg) 125 ± 19 127 ± 19 132 ± 24 n.s.
Diastolic blood pressure (mmHg) 74 ± 14 77 ± 15a 79 ± 18 0.012
Urinary protein-creatinine ratio 1.1 ± 1.6 2.1 ± 1.9a 3.9 ± 3.2a,b <0.0001
Urinary haematuria 2.1 ± 1.0 2.4 ± 0.9a 2.8 ± 0.5a <0.0001
Serum albumin (g/dl) 4.3 ± 0.5 4.1 ± 0.6a 3.7 ± 0.6a,b <0.0001
Serum creatinine (mg/dl) 0.9 ± 0.6 1.0 ± 0.4 1.5 ± 1.0a,b <0.0001
Serum uric acid (mg/dl) 5.5 ± 1.6 5.7 ± 1.6 6.3 ± 1.5a 0.016
Serum total cholesterol (mg/dl) 193 ± 43 205 ± 43a 238 ± 54a,b <0.0001
Serum triglycerides (mg/dl) 120 ± 100 118 ± 68 190 ± 118a,b 0.0001
Serum IgA (mg/dl) 362 ± 121 385 ± 135 313 ± 116b 0.004
Histological grade, n (%) aa ,b <0.0001
Grade I (glomerular score 1 or 2) n (%) 112 (23.6) 1 (0.5) 1 (2.9)
Grade II (glomerular score 3 or 4) n (%) 169 (35.7) 37 (19.1) 2 (5.9)
Grade III (glomerular score 5 or 6) n (%) 112 (23.6) 82 (42.3) 9 (26.5)
Grade IV (glomerular score 7 or 8) n (%) 71 (15.0) 60 (30.9) 14 (41.2)
Grade V (glomerular score ≥9) n (%) 10 (2.1) 14 (7.2) 8 (23.5)
Use of ACE-I or ARB, number/total 133/441 90/187a 18/32a <0.0001
Tonsillectomy, number/total 15/418 7/173 6/32a,b 0.003
ESRF, end-stage renal failure; n.s, not significant difference; no steroid, no steroid therapy; oral steroid, oral prednisolone therapy; pulse, 1000 mg
of methyl-prednisolone pulse therapy followed by oral prednisolone; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor
blocker.
Duration of follow-up is median (range).
Values are frequencies or means ± standard deviation or frequencies.
aSignificantly different compared to the no steroid group.
bSignificantly different compared to the oral steroid group.
Note: To convert serum creatinine in mg/dl to µmol/l, multiply by 88.4. To convert serum uric acid in mg/dl to µmol/l, multiply by 59.5. To convert
triglyceride in mg/dl to mmol/l, multiply by 0.0113. To convert cholesterol in mg/dl to mmol/l, multiply by 0.026. To convert serum IgA in mg/dl to g/l,
multiply by 0.01.
within 1 year of the follow-up. The mean age at biopsy was
33 ± 14 years. There were 295 men and 407 women. The
mean systolic or diastolic blood pressure (DBP) was 126 ±
19 mmHg and 75 ± 14 mmHg, respectively. The mean UP-
UCR was 1.5 ± 1.9, and the mean degree of haematuria
was 2.2 ± 0.9. The mean serum creatinine level was 0.98 ±
0.58 mg/dl (87 ± 51 µmol/l). The mean serum IgA level
was 366 ± 126 mg/dl (3.66 ± 1.26 g/l).
One hundred fourteen patients were classified in histo-
logical grade I, 208 in grade II, 203 in grade III, 145 in
grade IV and 32 in grade V .
Out of 702 patients, 228 patients were treated with
steroids. Two hundred forty-one were treated with ACE-I
or ARB. Of these, 167 were hypertensive and the remain-
ing 74 patients were normotensive. During the follow-up,
28 patients had tonsillectomy.
The baseline characteristics in each treatment groups
Methylprednisolone(mPSL)pulsetherapy,1g/dayforthree
consecutive days followed by 30 mg of PSL, was under-
taken in 34 patients (pulse steroid group). PSL was tapered
andmaintainedforatleast2years.Oralsteroidtherapywas
givento194patients(oralsteroidgroup).In46patients,ini-
tialdoseofPSLwas60mgfor4weeksandPSLwastapered
offwithin1year.In148patients,theinitialdoseofPSLwas
20 mg or 30 mg for 1 month. PSL was tapered and main-
tained for at least 2 years. The remaining 474 patients were
treatedwithananti-plateletagentorwithnomedication(no
steroid group). Table 2 shows the baseline characteristics in
each treatment group. UP-UCR was significantly different
among groups and was 1.1 ± 1.6, 2.1 ± 1.9 and 3.9 ±
3.2 in no steroid, oral steroid and pulse steroid groups,
respectively. UP-UCR was significantly higher in both
oral and pulse steroid group than in the no steroid group
(P<0.0001). Furthermore, UP-UCR was significantly
higher in the pulse steroid group than in the oral steroid
group (P<0.0001). Serum creatinine was 0.9 ± 0.6, 1.0 ±
0.4 and 1.5 ± 1.0 in the no steroid, oral steroid and pulse
groups, respectively, and was significantly higher in the
pulse steroid patients compared to the other two groups.
The severity of histological grade was significantly differ-
ent among treatment groups. In the no steroid group, the
percentageofpatientswithhistologicalgradeI–Vwas23.6,
35.7, 23.6, 15.0 and 2.1, respectively. In the oral steroid
group, the percentage of patients with histological grade
I–V was 0.5, 19.1, 42.3, 30.9 and 7.2, respectively. The per-
centageofpatientswithhistologicalgradeI–Vwas2.9,5.9,
26.5, 41.2 and 23.5, respectively, in the pulse steroid group.
Thehistologicalgradewashighestinthepulsesteroidgroup
followed by the oral steroid group and lowest in the no
steroid patients.3918 R. Katafuchi et al.
Fig. 1. Kidney survival curve in each histological grade. The patients
with histological grades I and II were analysed together due to the small
number of end-stage renal failure incidence. Kidney survivals signifi-
cantly differed among the histological grades (P<0.0001). The numbers
of patients remaining at 60, 120 and 180 months of follow-up in each
histological grade are shown at the bottom.
Cumulative kidney survival in all patients
During the follow-up period, 85 patients developed ESRF.
The cumulative kidney survival rate was 92.1% at 5 years
and 81.6% at 10 years from biopsy.
Kidney survival rate according to histological grade
analysed by the life table method
The kidney survival curve analysed by thelifetablemethod
ineachhistologicalgradeisshowninFigure1.Thepatients
with histological grades I and II were analysed together due
to the small number of ESRF incidence. Five-year kidney
survival in grade I+II, III, IV and V was 99.3, 97.5, 80.5
and 36.7%, respectively. Ten-year kidney survival in grade
I+II, III, IV and V was 95.6, 88.3, 57.2 and 24.5%, re-
spectively. Kidney survivals differed significantly among
the histological grades (P<0.0001).
Risk factors for the development of ESRF
Crude or multivariate-HRs for the development of ESRF
are shown in Table 3. In crude analysis, age, UP-UCR,
serum creatinine, histological grade, systolic blood pres-
sure (SBP), serum total cholesterol, serum triglyceride and
serum uric acid significantly increased the risk of develop-
ing ESRF. HR of ESRF for women was significantly lower
than men. Higher serum albumin was associated with a
significant risk reduction of ESRF.
In multivariate analysis, UP-UCR, serum creatinine,
serum triglycerides and serum uric acid significantly in-
creased the risk of the development of ESRF (P<0.05,
P<0.01, P<0.05, P<0.05, respectively). Serum albu-
min significantly decreased the risk of ESRF (P<0.01).
Multivariate adjusted HRs for the development of ESRF in
histological grades III, IV and V were 3.56, 8.64 and 5.74,
respectively, and significantly increased compared to grade
I+II(P<0.05,P<0.01,P<0.05,respectively).Asforthe
steroid treatment, HR of steroid pulse therapy decreased
significantly compared to the no steroid group (HR 0.14,
95%CI0.05–0.44,P<0.01).Ontheotherhand,HRforthe
developmentofESRFoftheoralsteroidgroupdidnotshow
any significant difference compared to the no steroid group
(HR0.61, 95% CI 0.30–1.22). These findings were stillob-
served even in the analysis using the time-dependent Cox
hazard model withthestatusof steroidtreatment duringthe
follow-up (oral steroid, HR 0.58, 95% CI 0.29–1.17; pulse
therapy, HR 0.15, 95% CI 0.05–0.43, P<0.01). The use
of ACE-I or ARB significantly decreased the risk of renal
death (P<0.01). Age, sex, serum total cholesterol, tonsil-
lectomy and SBP did not show any association with ESRF
in multivariate analysis. We selected SBP rather than DBP
in the multivariate analysis, because the likelihood ratio of
the model for SBP showed better fitting than that for DBP.
Adverse effect
In the oral steroid group, two patients developed steroid-
inducedpsychosisandweretreatedwellbythepsychiatrist.
One patient refused to take PSL after 8 months because
of palpitation, increased perspiration and facial blushing.
Three patients complained of insomnia and palpitation but
were able to tolerate the protocol. One patient had aseptic
necrosis of medial epicondyle of left femoral bone after
two courses of the low-dose protocol of PSL treatment.
The duration between the beginning of PSL and the onset
of left knee pain was 6 years. Another patient developed
diabetes mellitus, and PSL was tapered immediately. One
patient suffered from herpes zoster after 4-month steroid
therapy and was treated with aciclovir. In the mPSL pulse
group, one patient developed tuberculosis of left cervical
lymph node 4 months after the beginning of mPSL and was
successfully treated with anti-tubercular agents. The other
two patients developed herpes zoster 4 or 5 months after
steroid therapy and were treated with acyclovir.
Discussion
A variety of studies have been investigated to confirm the
effect of steroid treatment on amelioration of the clinical
course of IgAN [1–17]. However, the efficacy of steroid
therapy in patients with IgAN has not yet been established.
In our hospital, the treatment of IgAN patients has
changed over time. Since the initial 1986 publication of
the effects of steroids in IgAN by Kobayashi et al.[ 1 ] ,w e
started a pilot study of steroid treatment with 60 mg of
PSL as initial dose, gradually tapered off within 1 year.
We realized the necessity for a RCT to assess the efficacy
of steroid treatment in IgAN and performed between 1991
and 1995 a RCT in IgAN with a glomerular score ranging
from 4 to 7. A low-dose PSL protocol (initial dose of PSL;
20 mg/day) showed only an anti-proteinuric effect and
no effect on kidney survival [18]. Moreover, the protocol
failed to demonstrate an anti-proteinuric effect in patients
with massive proteinuria, i.e. UP-UCR exceeding 3. Since
the amount of proteinuria has been reported to be one
of the most important prognosticators in IgAN [21–25] and
the effect of steroid therapy on preventing the progressionThe improvement of renal survival with steroid pulse therapy 3919
Table 3. Crude or multivariate-adjusted hazard ratios for the development of end-stage renal failure
Univariate analysis Multivariate analysis
(backward method)
Risk factor Scale HR 95% CI HR 95% CI
Age (years) (every 10 years) 1.43 (1.23–1.66)∗∗ 1.03 (0.81–1.31)
Women (versus men) 0.52 (0.34–0.80)∗∗ 1.29 (0.67–2.47)
UP-UCR (every 1) 1.29 (1.22–1.35)∗∗ 1.16 (1.02–1.31)∗
Serum creatinine (every 1 mg/dl) 3.91 (3.26–4.69)∗∗ 3.95 (2.50–6.25)∗∗
SBP (every 10 mmHg) 1.34 (1.21–1.48)∗∗ 1.03 (0.87–1.20)
Serum albumin (every 1 g/dl) 0.27 (0.19–0.37)∗∗ 0.49 (0.29–0.84)∗∗
Serum total cholesterol (every 10 mg/dl) 1.01 (1.04–1.13)∗∗ ––
Serum triglycerides (every 10 mg/dl) 1.00 (1.03–1.06)∗∗ 1.03 (1.00–1.06)∗
Serum uric acid (every 1 mg/dl) 1.57 (1.40–1.75)∗∗ 1.3 (1.04–1.63)∗
Histological grade
Grade I+II (glomerular score 1–4) 1 (reference) 1 (reference)
Grade III (glomerular score 5 or 6) 3.58 (1.40–9.14)∗∗ 3.56 (1.11–11.39)∗
Grade IV (glomerular score 7 or 8) 16.5 (7.04–38.79)∗∗ 8.64 (2.66–28.05)∗∗
Grade V (glomerular score ≥9) 73.9 (29.07–187.78)∗∗ 5.74 (1.31–25.08)∗
Steroid therapy
No steroid 1 (reference) 1 (reference)
Oral steroid 0.88 (0.54–1.46) 0.61 (0.30–1.22)
Pulse steroid 2.6 (1.18–5.71)∗ 0.14 (0.05–0.44)∗∗
Use of ACE-I or ARB (versus no use) 1.09 (0.66–1.81) 0.39 (0.21–0.71)∗∗
Tonsillectomy (versus no tonsillectomy) 0.86 (0.27–2.74) – –
UP-UCR, urinary protein-creatinine ratio; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; SBP, systolic blood
pressure; HR, hazard ratio.
∗P<0.05, ∗∗P<0.01.
of IgAN is believed to link closely to reduction in urinary
protein[14,26],wespeculatedthatalow-dosePSLprotocol
was insufficient for the treatment of IgAN with moderate
histological severity. Steroid pulse therapy has been done
in such patients as those with a glomerular score ≥8, UP-
UCR exceeding 3.5 g/day and/or elevated serum creatinine
level.
Although the present study is retrospective and it is the
limitation of this study, we do believe that it is worthy to
reportourexperienceofsteroidtreatmentinalargenumber
of Japanese patients with IgAN in a single centre. We used
a multivariate analysis using the Cox proportional hazard
model.
Inthepresentstudy,wefoundthattheinfluenceofsteroid
therapy on the risk of ESRF was differed between the oral
and pulse steroid therapy. The HR for the development of
ESRF in the patients with steroid pulse therapy decreased
significantlycomparedtothenosteroidgroup.Ontheother
hand, the impact of oral steroid on the risk of ESRF did not
reach statistical significance.
Yoshimura et al. first reported the efficacy of mPSL
pulsetherapyonpreventingtheprogressionineightpatients
with IgAN showing crescent 10% or more of glomeruli
[6]. Two or three courses of 1 g/day mPSL for three con-
secutive days followed by oral PSL 20 mg/day tapered to
5–10 mg was administrated. Urinary protein excretion sig-
nificantly decreased, and creatinine clearance significantly
increased. After the pulse therapy, they performed second
biopsies and found a complete loss or marked decrease in
cellular crescent. They suggested that mPSL pulse therapy
prevents the progression of IgAN through suppression of
new crescent formation as well as transformation of cel-
lular crescent to fibrocellular or fibrous crescent. Hotta
et al. [11] also reported that not oral but pulse steroid ther-
apy showed a significant effect on remission of proteinuria
and haematuria in their retrospective study using multivari-
ate analysis. They also found that clinical remission was
closely related to stable kidney function. Their findings are
compatible with our results. In 1999, Pozzi et al. reported
a multicentre, randomized and controlled trial designed to
compare the effects of a 6-month steroid course with those
of supportive therapy in 86 patients with IgAN [14]. Their
steroid regimen was three courses of intravenous mPSL,
1g/dayforthreeconsecutivedaysplusoralPSL,0.5mg/kg,
on alternate days for 6 months. After 5 years of follow-
up, the risk of a doubling in plasma creatinine levels was
significantly lower in the treated patients. Recently, they
reported a long-term outcome of their previous control
trial [17]. Ten-year renal survival was significantly better
in the steroid than in the control group (97% versus 53%,
P=0.0003).Theend-pointofrenalsurvivalwasadoubling
in baseline plasma creatinine levels. The protective effect
ofmPSLpulsetherapyagainsttheprogressionofIgANwas
demonstrated as level-one evidence by their control trial. In
the present study multivariate analysis showed that steroid
pulse therapy had a significant effect on lowering the risk
for the development of ESRF. Considering that the patients
treated with steroid pulse therapy were clinically and histo-
logically the most severe cases, steroid pulse therapy seems
to be the most effective method among various steroid pro-
tocols. However, in our study, the number of patients who
received mPSL pulse therapy was only 34. A RCT, which
compare the effectiveness of oral steroid and that of pulse
steroid therapy, is necessary to reach a conclusion. So far
such studies have not yet been reported.
As for the adverse effects of steroid treatment, we got
an important message from the patients. Irrespective of the
method of steroid therapy, infections such as herpes zoster3920 R. Katafuchi et al.
and lymph node tuberculosis occurred 4–5 months after the
initiation of steroid treatment. We should have paid more
attention to prevent such infection during steroid therapy.
One patient with low-dose oral steroid treatment developed
aseptic necrosis of femoral bone after 6 years of steroid
therapy. Long-term steroid therapy should be avoided even
with low-dose protocol.
We reported previously that the glomerular score related
significantly to the outcome of 248 patients with IgAN
in univariate life table analysis [19]. In the present study,
we reconfirmed the usefulness of the glomerular score to
predict the prognosis in 702 patients with IgAN by multi-
variate analysis. We have applied steroid pulse therapy in
IgANwithhistologicalgradeoverIII,thatis,theglomerular
score ≥5.
In conclusion, we found that pulse steroid therapy im-
proved kidney survival in IgAN. Since the clinical findings
and histological grade were the most severe in patients
treated with mPSL pulse therapy, such therapy may prevent
progression of IgAN.
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